Purpose@#
Liver grafts from
donors with HBV
infection contributed to expanding the
donor pool under the
hepatitis B immunoglobulin and
antiviral agents (nucleos(t)ide analogues) in the HBV-endemic area. We
report long-term outcomes of
liver transplantations (LTs) using
grafts from
donors with active or chronic HBV
infection. @*
Methods@#Overall, 2,260 LTs performed in 3 major
hospitals in
Seoul from January 2000 to April 2019 were assessed for inclusion. Twenty-six
grafts (1.2%) were obtained from
HBsAg (+), HBeAb (+), or HBcAb (+)
donors, and recipient outcomes were retrospectively reviewed.
Donor and recipient demographics and
transplantation outcomes were analyzed. @*Results@#Sixteen deceased
donor LTs were performed using active
HBsAg (+)
grafts. Ten other LTs were sourced from 10
living donors. There was no significant difference in
survival in
patients who received deceased
donor LTs compared with that in those
who underwent LT with non–
hepatitis virus-infected
grafts. Fourteen
patients who were followed up for >5 years were stable, and no difference in
hepatocellular carcinoma recurrence rate was observed 5 years after
transplantation between
transplants from
donors with and those without HBV. @*Conclusion@#Considering long-term outcomes,
liver grafts from
donors with active HBV replication can be safely used for LT.